---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034489"
form_type: "8-K/A"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:18:47.334827+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# MindMed 2023 annual meeting: company slate elected, FCM nominees defeated

## Summary
- Final voting results certified July 25, 2023; unchanged from preliminary results of June 27.
- All six company board nominees elected (e.g., Robert Barrow 8.15M for vs 6.26M withheld).
- All four FCM MM Holdings nominees failed; each had more withheld votes (e.g., Dr. Scott Freeman 6.02M for, 7.78M withheld).
- KPMG LLP reappointed as auditor (14.86M for, 0.39M against, 1.08M abstain).
- Quorum 42.3% of 38.59M outstanding shares; meeting held June 21.

## SEC filing metadata
- accession: 0000950170-23-034489
- form_type: 8-K/A
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017023034489/0000950170-23-034489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017023034489/mnmd-20230621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034489
- JSON: https://secwatch.observer/filing/0000950170-23-034489.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034489.txt

## Key facts
- Shareholder Votes
  Definium Therapeutics, Inc. shareholders approved Election of Directors at the 2023-07-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-07-25
  source text: The Company’s six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Company’s Board of Directors (the “Board”) until the 2024 annual general meeting of shareholders (the “2024 Annual Meeting”) and until his or her successor is duly elected or qualified, by the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023034489/0000950170-23-034489-index.htm
- Shareholder Votes
  Definium Therapeutics, Inc. shareholders approved Appointment of Auditor at the 2023-07-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-07-25
  source text: The shareholders approved the appointment of KPMG LLP as the auditor of the Company until the close of the 2024 Annual Meeting, by the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023034489/0000950170-23-034489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.